323 related articles for article (PubMed ID: 38732253)
1. Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus.
Graczyk P; Dach A; Dyrka K; Pawlik A
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732253
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.
Alonso N; Moliner P; Mauricio D
Adv Exp Med Biol; 2018; 1067():197-217. PubMed ID: 28980272
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.
Khan S; Ahmad SS; Kamal MA
Endocr Metab Immune Disord Drug Targets; 2021; 21(2):268-281. PubMed ID: 32735531
[TBL] [Abstract][Full Text] [Related]
4. The latest emerging drugs for the treatment of diabetic cardiomyopathy.
Li M; Liu L; Zhang C; Deng L; Zhong Y; Liao B; Li X; Wan Y; Feng J
Expert Opin Pharmacother; 2024 Apr; 25(6):641-654. PubMed ID: 38660817
[TBL] [Abstract][Full Text] [Related]
5. Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M; Li Y; Li S; Lv J
Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
[TBL] [Abstract][Full Text] [Related]
6. Curcumin protects cardiomyopathy damage through inhibiting the production of reactive oxygen species in type 2 diabetic mice.
Wu X; Huang L; Zhou X; Liu J
Biochem Biophys Res Commun; 2020 Sep; 530(1):15-21. PubMed ID: 32828278
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway.
Arad M; Waldman M; Abraham NG; Hochhauser E
Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106454. PubMed ID: 32413571
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.
Jakubik D; Fitas A; Eyileten C; Jarosz-Popek J; Nowak A; Czajka P; Wicik Z; Sourij H; Siller-Matula JM; De Rosa S; Postula M
Cardiovasc Diabetol; 2021 Feb; 20(1):55. PubMed ID: 33639953
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin.
Xu N; Liu S; Zhang Y; Chen Y; Zuo Y; Tan X; Liao B; Li P; Feng J
Redox Rep; 2023 Dec; 28(1):2246720. PubMed ID: 37747066
[TBL] [Abstract][Full Text] [Related]
10. Antioxidative Effects of Natural Products on Diabetic Cardiomyopathy.
Yan B; Ren J; Zhang Q; Gao R; Zhao F; Wu J; Yang J
J Diabetes Res; 2017; 2017():2070178. PubMed ID: 29181412
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
Packer M
Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
[TBL] [Abstract][Full Text] [Related]
12. Pyroptosis: Mechanisms and links with diabetic cardiomyopathy.
Liu P; Zhang Z; Chen H; Chen Q
Ageing Res Rev; 2024 Feb; 94():102182. PubMed ID: 38182080
[TBL] [Abstract][Full Text] [Related]
13. An Insight into the Pathogenesis of Diabetic Cardiomyopathy Along with the Novel Potential Therapeutic Approaches.
Vig H; Ravinandan AP; Vishwas HN; Tyagi S; Rathore S; Wal A; Wal P
Curr Diabetes Rev; 2024; 20(1):e020523216416. PubMed ID: 37138437
[TBL] [Abstract][Full Text] [Related]
14. Diabetic cardiomyopathy: a brief summary on lipid toxicity.
Ke J; Pan J; Lin H; Gu J
ESC Heart Fail; 2023 Apr; 10(2):776-790. PubMed ID: 36369594
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.
Dei Cas A; Spigoni V; Ridolfi V; Metra M
Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):38-50. PubMed ID: 23369136
[TBL] [Abstract][Full Text] [Related]
16. Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways.
Joubert M; Manrique A; Cariou B; Prieur X
Diabetes Metab; 2019 Jun; 45(3):238-247. PubMed ID: 30078623
[TBL] [Abstract][Full Text] [Related]
17. Tiny molecule, big power: Multi-target approach for curcumin in diabetic cardiomyopathy.
Karuppagounder V; Arumugam S; Giridharan VV; Sreedhar R; Bose RJ; Vanama J; Palaniyandi SS; Konishi T; Watanabe K; Thandavarayan RA
Nutrition; 2017 Feb; 34():47-54. PubMed ID: 28063511
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate.
Al Hroob AM; Abukhalil MH; Hussein OE; Mahmoud AM
Biomed Pharmacother; 2019 Jan; 109():2155-2172. PubMed ID: 30551473
[TBL] [Abstract][Full Text] [Related]
19. Streptozotocin-induced type II diabetic rat administered with nonobesogenic high-fat diet is highly susceptible to myocardial ischemia-reperfusion injury: An insight into the function of mitochondria.
Ansari M; Gopalakrishnan S; Kurian GA
J Cell Physiol; 2019 Apr; 234(4):4104-4114. PubMed ID: 30191974
[TBL] [Abstract][Full Text] [Related]
20. Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy.
Zhang XJ; Han XW; Jiang YH; Wang YL; He XL; Liu DH; Huang J; Liu HH; Ye TC; Li SJ; Li ZR; Dong XM; Wu HY; Long WJ; Ni SH; Lu L; Yang ZQ
Int Immunopharmacol; 2023 Oct; 123():110747. PubMed ID: 37586299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
